Iovance Biotherapeutics, Inc.
IOVA
$2.45
-$0.08-3.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 21.55% | -33.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 21.55% | -33.07% | |||
| Cost of Revenue | 13.92% | 9.22% | |||
| Gross Profit | 888.49% | -101.48% | |||
| SG&A Expenses | -14.17% | 3.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.87% | 6.41% | |||
| Operating Income | 6.14% | -40.02% | |||
| Income Before Tax | 7.06% | -53.25% | |||
| Income Tax Expenses | 208.16% | -217.97% | |||
| Earnings from Continuing Operations | 3.88% | -47.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.88% | -47.87% | |||
| EBIT | 6.14% | -40.02% | |||
| EBITDA | 7.35% | -44.80% | |||
| EPS Basic | 7.23% | -39.62% | |||
| Normalized Basic EPS | 11.91% | -42.26% | |||
| EPS Diluted | 7.23% | -39.62% | |||
| Normalized Diluted EPS | 11.91% | -42.26% | |||
| Average Basic Shares Outstanding | 3.61% | 5.90% | |||
| Average Diluted Shares Outstanding | 3.61% | 5.90% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||